Referenties bij MAGMA 4-2014

Referenties bij MAGMA 4-2014
Propofol: zegen of bedreiging, p. 126-127
1. Behrens A, Labenz J, Schuler A, et al. How safe is sedation in gastrointestinal
endoscopy? A multicentre analysis of 388,404 endoscopies and analysis of data from
prospective registries of complications managed by members of the Working Group of
Leading Hospital Gastroenterologists. Z Gastroenterol 2013;May;51(5):432–6.
2. Shin S, Lee SK, Min KT et al. Sedation for interventional gastrointestinal endoscopic
procedures: are we overlooking the “pain”? Surg Endosc 2014; Jan;28(1):100–7.
3. Zippi M, De Felici I, Pica R et al. Endoscopic papillary balloon dilatation for difficult
common bile duct stones: our experience.
World J Clin Cases 2013;Apr;16(1):19–24
4. Park CH, Kim H, Kang YA et al. Risk factors and prognosis of pulmonary
complications after endoscopic submucosal dissection for gastric neoplasia.
Dig Dis Sci 2013;Feb;58(2):540–6
5. Wang D, Chen C, Chen J et al. The use of propofol as a sedative agent in
gastrointestinal endoscopy: a meta-analysis. PLoS One 2013; 8(1):e53311
6. Sethi S, Wadhwa V, Thaker A, et al. Propofol versus traditional sedative agents
for advanced endoscopic procedures: a meta-analysis.
Dig Endoscop 2014;Jul;26(4):515–24.
7. Vargo JJ, Bramley T, Meyer K, Nightengale B. et al. Practice efficiency and
economics: the case for rapid recovery sedation agents for colonoscopy in a screening
population. J Clin Gastroenterol 2007;Jul;41(6):591–8.
8. Hassan C, Rex DK, Cooper GS, Benamouzig R. Endoscopist-directed propofol
administration versus anesthesiologist assistance for colorectal cancer screening:
a cost-effectiveness analysis. Endoscopy 2012;May;44(5):456–64.
9. Kim EH, Lee SK. Endoscopist-directed propofol: pros and cons.
Clin Endosc 2014;Mar;47(2):129–34.
10. Sieg A, Beck S, Scholl SG et al. Safety analysis of endoscopist-directed propofol
sedation: a prospective, national multicenter study of 24 441 patients in German
outpatient practices. J Gastroenterol Hepatol 2014;Mar;29(3):517–23.
11. Adeyemo A, Bannazadeh M, Riggs T, et al. Does sedation type affect colonoscopy
perforation rates? Dis Colon Rectum 2014;Jan;57(1):110–4.
12. Okholm C, Hadikhadem T, Andersen LT et al. No increased risk of perforation during
colonoscopy in patients undergoing nurse administered propofol sedation. Scand J
Gastroenterol 2013;Nov;48(11):1333–8.
1
13. Rex DK, Deenadayalu VP, Imperiale TF et al. Endoscopist-directed administration of
propofol: a worldwide safety experience.
Gastroenterolgy 2009;Oct;137(4):1229–37.
14. Schilling D. Propofol-based sedation in gastrointestinal endoscopy: getting safer and
safer. Digestion 2014;89(4):272–3.
15. Cheriyan DG, Byrne MF. Propofol use in endoscopic retrograde
cholangiopancreatography and endoscopic ultrasound.
World J Gastroenterol 2014;May;20(18):5171–6.
16. Jensen JT, Konge L, Moller A et al. Endoscopy nurse-administered propofol sedation
performance. Development of an assessment tool and reliability-testing model. Scand
J Gastroenterol 2015;Aug;49(8):1014–9.
17. Kiriyama S, Naitoh, Kuwano H. Propofol sedation during endoscopic treatment for
early gastric cancer compared to midazolam.
World J Gastroenterol 2014;Sept;20(34):11985–11990.
18. Manickdam P, Kanaan Z, Zakaria K. Conscious sedation: a dying practice.
World J Gastroenterol 2013;Jul;19(28):4633–4.
19. Lera dos Santos ME, Maluf-Filho F, Chaves DM et al. Deep sedation during
gastrointestinal endoscopy: propofol-fentanyl and midazolam-fentanyl regimens.
World J Gastroenterol 2013;Jun;19(22):3439–46.
20. Triantafillidis JK, Merikas E, Nikolakis D, Papalois AE. Sedation in gastrointestinal
endoscopy: current issues. World J Gastroenterol 2013;Jan;19(4):463–81.
21. Cooper GS, Kou TD, Rex DK. Complications following colonoscopy with anesthesia
assistance. JAMA 2013;173(7):551–556.
22. Wernli KJ, Inadomi JM. Anesthesia for coloncopy. Too much of a good thing.
Jama 2013;173(7):556–558.
Oppassen met MDL-medicatie bij kwetsbare ouderen! p. 137
1. Jansen PAF, Brouwers JRBJ. Clinical Pharmacology in Old Persons. Scientifica 2012;art
ID723678 (ePub gratis te downloaden of via ephor.nl)
2. Huisman-Baron et al. Criteria for Drug Selection in Elderly. Drugs and Aging
2011;28(5)391-402.
2
Casuïstiek: Anti-TNF-α en ipilumumab-geassocieerde colitis, p. 141
1. Oncoline, www.oncoline.nl, richtlijn over melanoom, behandeling bij gemetastaseerde
ziekte.
2. Khirfan K, Kistin M, Colitis associated with biological agents, Dig Dis Sci 2014;59;1112–
1114
3. Merrill SP, Reynolds P, Kalra A, Biehl J, Vandivier RW, Mueller SQ, Early
administration of Infliximab for severe Ipilimumab-related diarrhea in a critically ill
patient, Ann pharmacother. 2014; Jun;48(6):806–10.
4. Johnston RL, Lutzky J, Chodhry A, Barkin JS, Cytotoxic T-lymphocyte-associated
antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis
Sci 2009;54:2538–2540.
5. Slangen RM, van den Eertwegh AJ, van Bodegraven AA, de Boer NKH, Diarrhoea in a
patient with metastatic melanoma: Ipilimumab ileocolitis treated with infliximab World J
Gastrointest Pharmacol Ther 2013;Aug 6;4(3):80–2.
6. Nardone B, Hammel JA, Raisch DW, Weaver LL, Schneider D, West DP, Melanoma
associated with tumor necrosis factor-a inhibitors, a research on adverse drug events and
reports project, Br J Dermatol 2014; May;170(5):1170–2.
7. Farmacotherapeutisch kompas, www.fk.cvz.nl
3

Download Report